Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PF-06835375

Small molecule · developed by PFIZER

Phase 2 Most advanced trial (none active)
PFE Developer

What is PF-06835375?

PF-06835375 is a drug studied in primary immune thrombocytopenia, a condition marked by low platelet counts.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Hematology
Developer
PFIZER (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Primary Immune Thrombocytopenia

More from PFIZER

Follow PFE, the company behind PF-06835375

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.